02561.HK
VISEN Pharmaceuticals
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 13.93
−0.50%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 20.4M | 160.7K | 2.8M | (1.7M) | — |
| Cost of Revenue | 16.6M | 142.2K | — | — | — |
| Gross Profit | 3.8M | 18.5K | 2.8M | (1.7M) | (2.3M) |
| Operating Expenses | |||||
| R&D Expense | 84.2M | 91.1M | 90.5M | 57.7M | 179.5M |
| SG&A Expense | 155.7M | 146.3M | 86.4M | 16.4M | 41.5M |
| General & Admin Expense | 88.7M | 115.1M | 86.4M | 16.4M | 41.5M |
| Selling & Marketing Expense | 67.0M | 31.2M | — | — | — |
| Other Expenses | — | (3.8M) | (2.8M) | 64.8M | 137.2M |
| Total Operating Expenses | 239.9M | 233.6M | 174.2M | 138.8M | 358.3M |
| Cost and Expenses | 256.5M | 233.7M | 177.0M | 137.6M | 358.3M |
| Operating Income (EBIT) | (236.1M) | (233.6M) | (174.2M) | (138.8M) | (358.3M) |
| Non-Operating | |||||
| Interest Income | — | 11.5M | 6.8M | 11.1M | 5.6M |
| Interest Expense | — | 1.1M | 161.0K | 317.0K | 619.0K |
| Net Interest Income | 3.5M | 10.4M | 6.6M | 10.8M | 4.9M |
| Other Non-Op Income/Expense | (3.4M) | (13.3M) | (8.1M) | (110.7M) | 69.3M |
| Non-Operating Income (excl Interest) | — | 11.8M | 7.9M | 110.4M | (69.9M) |
| EBT (Pre-Tax Income) | (239.5M) | (246.9M) | (182.2M) | (249.6M) | (289.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (239.5M) | (246.9M) | (182.2M) | (249.6M) | (289.0M) |
| Earnings from Cont. Ops | (239.5M) | (246.9M) | (182.2M) | (249.6M) | (289.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (239.5M) | (246.9M) | (182.2M) | (249.6M) | (289.0M) |
| Per Share | |||||
| Basic EPS | (HK$2.20) | (HK$2.38) | (HK$1.95) | (HK$2.67) | (HK$3.09) |
| Diluted EPS | (HK$2.20) | (HK$2.38) | (HK$1.95) | (HK$2.67) | (HK$3.09) |
| Revenue Per Share | HK$0.19 | HK$0.00 | HK$0.03 | (HK$0.02) | HK$0.00 |
| Shares | |||||
| Basic Shares Outstanding | 109.6M | 103.7M | 93.6M | 93.6M | 93.6M |
| Diluted Shares Outstanding | 109.6M | 103.7M | 93.6M | 93.6M | 93.6M |
| Profitability Metrics | |||||
| EBITDA | (233.1M) | (236.7M) | (177.6M) | (242.3M) | (281.0M) |
| D&A | 3.0M | 3.2M | 4.5M | 7.0M | 7.4M |
| EBIT | (236.1M) | (239.8M) | (182.1M) | (249.3M) | (288.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026